Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain

NCT00472303 is registered in ClinicalTrials.gov with Grünenthal GmbH as lead sponsor.

NCT NCT00472303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00472303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain
Lead sponsor
Grünenthal GmbH
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
June 30, 2012
Enrollment
622 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

pain, tumor